| Metric | შპს ბიოპოლუსი | შპს ნეოფარმი | სს ინოვას |
|---|---|---|---|
| Growth | |||
| Revenue | ₾6.5m₾12.8m | ₾19.2m₾15.4m | ₾5.0m₾1.9m |
| Revenue growth | -49.1% | 25.0% | 165.0% |
| Profitability | |||
| EBITDA | ₾1.9m₾3.4m | -₾376k-₾1.3m | ₾2.8m₾549k |
| EBITDA margin | 29.2%26.7% | -2.0%-8.5% | 56.5%29.1% |
| Net profit | ₾1.5m₾3.4m | -₾589k-₾1.5m | ₾2.7m₾378k |
| Net margin | 23.6%26.3% | -3.1%-9.5% | 54.8%20.0% |
| Balance sheet | |||
| Total assets | ₾14.7m₾13.6m | ₾8.0m₾8.5m | ₾6.3m₾4.0m |
| Total equity | ₾11.7m₾10.2m | ₾5.1m₾6.1m | ₾5.5m₾3.2m |
| ROE | 13.1%33.0% | -11.6%-23.8% | 49.8%11.7% |